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Objective: To evaluate the pharmacokinetics and tissue distribution of liposomal brucine (LB) 
for dermal application.
Methods: Pharmacokinetics and tissue distribution were studied by in vivo animal testing. High 
performance liquid chromatography (HPLC) was used to detect the concentration of brucine in 
rats’ skin, plasma and various tissues.
Results: After dermal administration, LB was absorbed rapidly in the skin and could be detected 
after 0.5 hours. After 36 hours, levels were too low to be detected. In plasma, levels were also 
too low to be detected after 36 hours. The concentration of LB reached 50% of the maximum 
in all tissues except the brain, peaking after 1.5 hours but still detectable after 12 hours.
Conclusion: The concentration of LB was high in skin at the application site. LB was quickly 
absorbed into tissues through the blood circulation and widely distributed throughout the whole 
body. There was no obvious toxicity and LB did not readily accumulate in tissues and organs. 
It showed local potency but low overall systemic toxicity.
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Introduction
Brucine is an alkaloid and exists mainly in the seeds of Strychnos nux-vomica L 
(Loganiaceae),1 which is widely used in China. The chemical structure of brucine is 
shown in Figure 1.
Brucine is known as an anti-inflammatory and analgesic drug for relieving pain 
due to arthritis and injuries.2 Its main pharmacodynamic actions are to relieve pain, 
reduce swelling, and promote circulation. Unfortunately, the potential use of brucine is 
severely limited due to its high incidence of side effects, including violent convulsions 
and even lethal poisoning.3 To overcome this problem, liposomal brucine (LB) for 
transdermal delivery was developed. The in vivo experiments we describe demonstrate 
that after encapsulation, brucine exhibits an apparent decrease in toxicity and/or an 
increase in therapeutic efficacy.4–6 The effectiveness of brucine for analgesia and relief 
of swelling improves after encapsulation in nanometer-sized liposomes, and it exhibits 
sustained release; targeting,7–10 local potency and low systemic toxicity.11,12 Although 
great progress has made in research on LB, so far the absorption, pharmacokinetics 
(PK), tissue distribution and metabolism of this new transdermal drug delivery system 
remain unknown.
This study investigated the pharmacokinetics and the final tissue distribution of 
transdermally administered LB. The concentration of LB in rats’ skin, plasma and 
various tissues was measured by high performance liquid chromatography (HPLC).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Materials and methods
chemicals and reagents
Standard brucine (Cat. No. 110706-200505) and strychnine 
(Cat. No. 11705-200306) (as the internal standard) were 
purchased from the Shanghai Institute of Biological Prod-
ucts (Shanghai, China). Brucine was purchased from Fluka 
(Sigma Aldrich, Buchs, Switzerland). Diethylamine, dichlo-
romethane and ether (analytical grade) were obtained from 
Sinopharm Chemical Reagent (Shanghai, China). Methanol 
and acetonitrile (chromatographic grade) were obtained from 
Merck (Darmstadt, Germany). Water for HPLC was double-
distilled and all other reagents were analytical grade.
Preparation of liposomes
LB used in this study (95%) was prepared by the East 
China University of Science and Technology (Shanghai, 
China).11 A modified ethanol-dripping method was used to 
prepare LB.12 An ethanol solution of lipid (lecithin: cho-
lesterol = 6:1 w/w), sodium deoxycholate, Tween-80, and 
brucine (16:4:4:1, w/w) was dripped into mannitol solution 
(5.3 mg/mL). The ratio of the ethanolic-lipid phase to the 
aqueous phase was 1:9 (v/v) in the final suspension. The 
suspension was then sonicated (45 W; Shanghai Kedao 
Ultrasonic Instrument Co, Shanghai, China) in an ice 
water-bath for 20 minutes and freeze-dried for 72 hours. 
The dry powder was stored at -18°C in a freezer. The dry 
powder was rehydrated and sonicated for 3 minutes prior 
to application.11
Animals
Healthy Sprague-Dawley (SD) rats of both sexes, weighing 
180–220 g, were provided by the Experimental Animals 
Center of Fudan University (Shanghai, China). On arrival, 
the animals were acclimated for 7 days. The animals were 
housed in standard cages, maintained at a temperature of 
22 ± 2°C and 40%–70% relative humidity with 12 hour light/
dark cycles, and provided with fresh water and standardized 
diets ad   libitum, unless otherwise noted. The animal tests were 
  performed according to the Principles of Laboratory   Animal 
Care and Use in Research, Ministry of Health (Beijing, 
China). All animal experiments were approved by the Animal 
Ethics Committee, Ministry of Health (Beijing, China).
sample collection and treatment
One hundred and forty healthy SD rats were divided into 
two groups according to sex. LB suspension was smeared 
on the skin at the hypogastric zone at a dose of 6 mg/kg 
  (concentration of brucine administrated was 1 mg/kg).
skin PK study
Twelve hours before administration, the rats were shaved in 
the hypogastric zone. SD rats were anesthetized with ure-
thane (concentration 25%, dose rate 0.4 mL/100 g). About 
3 cm × 3 cm of skin was cut at 0.5, 2, 4, 8, 12, 14, 16, 18, 
20, 22, 24, 28 and 36 hours post-dosing according to a preset 
schedule.
Plasma PK study
1.5–2.0 mL blood samples were collected from the abdomi-
nal aorta at 0.5, 2, 4, 8, 12, 14, 16, 18, 20, 22, 24, 28 and 
36 hours after intravenous injection of brucine phosphate 
buffered saline solution or LB suspension, to study the 
sustained-release properties of the liposome delivery 
method.
Treatment
Skins were rinsed with water to remove remaining traces 
of blood before handling. A 0.5 g skin sample was homog-
enized at 0°C. Subsequently, 1 mL homogenate or 0.2 mL 
plasma was added to 20 µL internal standard (strychnine) 
and 2 mol/L NaOH. The solutions were vortex-mixed for 
10 minutes at 12,000 rpm after extracting with diethyl 
ether: methylene chloride (2:1). The upper organic layer 
was evaporated to dryness in a vacuum drying oven. The 
residue dissolved in the mobile phase was vortex-mixed for 
10 minutes at 12,000 rpm. From this, 20 µL supernatant was 
used for PK evaluation.
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Tissue distribution study
The brain, liver (superior lobe), kidney, heart, lung, spleen 
and femoribus internus muscle were removed from each 
anesthetized animal by gross dissection at 0.5, 1, 1.5, 2, 4, 
8 and 12 hours after dermal administration. Tissues were 
rinsed with water to remove remaining traces of blood 
before handling.
For each animal, 0.5 g of each tissue type was homog-
enized at 0°C, and then 1 mL homogenate was added into 
100 µL ammonia water and shaken slightly. Then 5 mL 
chloroform was added into the tube. The homogenate was 
vortex-mixed for 1 minute at 2900 rpm. Then the solution 
was sonicated for 40 minutes. The under layer (chloroform) 
was collected and was volatilized in a vacuum drying oven 
after incubating for 4 hours at 60°C. The residue dissolved 
in the mobile phase was vortex-mixed for 10 minutes at 
12,000 rpm. Subsequently 20 µL of the supernatant was 
used for chromatographic analysis. The content of brucine 
in each tissue sample was qualitatively and quantitatively 
analyzed by RP-HPLC.
Instrumentation and 
chromatographic conditions
HPLC was performed on an Agilent 1200 series system 
(Agilent Technologies, Waldbronn, Germany) equipped 
with a binary pump (G1312A), a thermostatically controlled 
column compartment and a UV detector. The separation of 
skin and plasma was achieved with a Thermo Hypersil ODS 
C18 Column (250 mm × 4.6 mm, 5 µm; Hypersil, Thermo 
Scientific, Waltham, MA) and CH3OH: H2O: (C2H5)2NH 
(55:45:0.2, v/v) was used as the mobile phase. The tissue 
distribution study was carried out using a Discovery C18 
Column (250 mm × 4.6 mm, 5 µm; Supelcosil, Sigma 
Aldrich, St Louis, MO). Acetonitrile: 10 mmol/L sodium 
heptanesulfonate balanced mixed with 20 mmol/L potas-
sium dihydrogen phosphate (pH was adjusted to 2.8 by 10% 
H3PO4) (21:79 v/v) was used as the mobile phase. Column 
temperature was at 30°C and flow speed was 1 mL/minute 
with wavelength set at 260 nm.
Parameter calculation
The active components in skin and tissue were analyzed by 
comparing the chromatographs of skin and tissue samples 
after the rats were given brucine standard preparation, with 
blank skin samples. The composition of plasma samples 
after transdermal drug delivery was analyzed by comparing 
the sample chromatographs with those of brucine standard 
preparations and control blood samples.
Brucine concentration and concentration-time response was 
calculated in skin using the DAS program.   Pharmacokinetics 
parameters were calculated using the statistical moment method. 
Data from tissue samples was analyzed using mean ± SD (stan-
dard deviation) and the difference between each group was 
compared using the variance. All statistical analysis used SPSS 
software (v 12.0; SPSS, Inc, Chicago, IL).
Results and discussion
characterization of liposomes
The average size of the liposomes was between 25 and 
110 nm, and the mean diameter was 55.4 nm, indicat-
ing a narrow population distribution. The encapsulation 
efficiency (EE) of LB determined by gel filtration was 
71.95% ± 2.65% (n = 4) (EE = [total drug–unencapsulated 
drug]/total drug × 100%). The average zeta-potential 
was -39.5 eV .
hPLc determination
Figures 3 and 4 illustrate the chromatography of brucine. 
It can be seen that there were no peaks at the same reten-
tion time in the blank sample as in the reference substance. 
The peak of brucine could be separated from other compo-
nents and there were no endogenous peaks interfering with 
brucine.
Figure 5 shows the HPLC chromatographs of bru-
cine extracted from different tissues after transdermal 
  administration. As shown, there were no new metabolites 
observed in the tissues. This implied that the chromatographic 
conditions used could be applied to the assay of brucine in 
different tissues in the following study.
skin PK study
Figure 6 shows the concentration-time curve of brucine levels 
in rat skin. It has been found that LB can be absorbed rapidly 
after administration and can be measured after 0.5 hours. 
Brucine concentration in skin changed over time, declining 
to below the limits of measurement (LOQ, 0.1 µg/mL) by 
36 hours after administration.
Tables 1 and 2 present the pharmacokinetics parameters 
calculated from female and male rat skin experiments, 
  respectively. From Table 1, it can be seen that the half-life 
of LB in female rat skin was about 3.1 hours. The drug 
content in skin reached a peak of 7.39 µg/g after 15.6 hours. 
From Table 2, it can be seen that the half-life of brucine 
liposomes in male rats’ skin was about 3.6 hours. Brucine 
concentration in skin peaked at 5.99 µg/g, 16 hours after 
administration.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 3 hPLc chromatographs of brucine. 
Notes: A, standard; B, Blank skin; c, Blank skin + standard; D, skin containing brucine; , Brucine; , Internal standard: strychnine.
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Figure 4 hPLc chromatographs of brucine.
Notes: A, standard; B, Blank Plasma; c, Blank Plasma + standard; D, Plasma containing brucine; , Brucine; , Internal standard: strychnine.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 5 hPLc chromatographs of brucine in each tissue sample after administration.
Notes: A, Liver; B, spleen; c, Kidney; D, heart; e, Brain; F, Lung; g, Muscle; B, Brucine; s, Internal standard: strychnine.
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Figure 6 concentration-time curve of brucine content in male and female rats (n = 5).
Notes: A, c-T curve Female rat skin; B, c-T curve of Male rat skin.
Abbreviation: c-T, concentration-time.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1114
Yang et al
Table 1 PK parameters for brucine in female rats’ skin (n = 5)
Parameter Unit Mean SD
t1/2z hours 3.14 0.31
tmax hours 15.60 0.89
cmax mg/L 7.39 0.61
cLz/F L/hours/kg 0.055 0.003
Vz/F L/kg 0.248 0.03
MrT(0-∞) hours 13.83 0.23
MrT(0-t) hours 13.71 0.24
AUc(0-t) mg/L × hours 109.40 5.50
AUc(0-∞) mg/L × hours 109.86 5.48
Note:*
Abbreviations:  AUc,  area  under  the  curve;  cLz,  clearance;  cmax,  maximum 
concentration;  F,  availability;  MrT,  mean  residence  time;  PK,  pharmacokinetics; 
t1/2, biological half-life; tmax, time to reach cmax; Vz, volume of distribution during 
terminal (Z) phase.
Table 2 PK parameters for brucine in male rats’ skin (n = 5)
Parameter Unit Mean SD
t1/2z hours 3.60* 1.13
tmax hours 16.00 1.41
cmax mg/L 5.99* 0.33
cLz/F L/hours/kg 0.055 0.003
Vz/F L/kg 0.283 0.071
MrT(0-t) hours 13.63 0.46
MrT(0-∞) hours 13.96 0.95
AUc(0-t) mg/L × hours 107.37 4.53
AUc(0-∞) mg/L × hours 108.68 6.20
Note: * P , 0.05 (compared with female).
Abbreviations:  AUc,  area  under  the  curve;  cLz,  clearance;  cmax,  maximum 
concentration; F, availability; MrT, mean residence time; PK, pharmacokinetics; t1/2, 
biological half-life; tmax, time to reach cmax; Vz, volume of distribution during terminal 
(Z) phase.
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Figure 7 concentration-time curve of brucine in plasma after intravenous injection 
of brucine solution (n = 5).
Abbreviations: Bru, brucine; c-T, concentration-time; iv, intravenous injection; 
PBs, phosphate buffered saline.
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Figure 8 concentration-time curve of brucine in plasma after intravenous injection 
of LB (n = 5).
Abbreviations: Bru, brucine; c-T, concentration-time; iv, intravenous injection; 
LB, liposomal brucine; lip, liposome.
Based on the above results, it can be concluded that the 
skin had a typical reservoir effect for liposome-encapsulated 
brucine. We found a sex difference in drug absorption among 
rats after transdermal delivery. For this reason, separate 
time-concentration curves were constructed for males and 
females. Pharmacokinetic parameters were calculated by 
statistical moments according to the noncompartment model. 
The concentration peak of LB in female rats’ skin was higher 
than that in male rats’ skin. However the half-life of LB in 
male rats’ skin was about 3.6 hours, which was longer than 
that in females (3.1 hours). This difference in the level of 
LB in the skin of the two sexes may be related to hormones, 
which often influence drug absorption.
Plasma PK study
Drug concentration in plasma was determined after LB 
was given by dermal administration. Brucine could not be 
detected in the plasma 36 hours after dermal administration. 
For accuracy, we studied the plasma pharmacokinetics of LB 
and normal brucine after intravenous injection.
Figures 7 and 8 show the concentration-time curves for 
LB and normal brucine in rats’ plasma. Tables 3 and 4 present 
the corresponding pharmacokinetics parameters.
It can be seen that the half-life of normal brucine   solution 
was about 0.9 hours and the half-life of LB was about 
2.4 hours. The half-life of LB was considerably longer than 
that of normal brucine. We believe this phenomenon could 
be attributable to the sustained-release effect associated with 
liposomes.
Tissue distribution study
The concentrations of LB in different tissues were deter-
mined 0.5, 1, 1.5, 2, 4, 8 and 12 hours after administration. 
It was found that brucine could distribute widely in different International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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rapid absorption and excretion. However the concentration in 
muscle was lower than in other tissues (except the brain).
A similar trend for LB concentration distribution 
was observed over time in a range of tissues after dermal 
  administration. The concentration of brucine increased at first 
and then declined over time, but the concentrations differed 
between types of tissue.
Based on these data, LB showed tissue selectivity. 
The concentrations in liver, kidney, spleen and lung were 
higher than in other tissues. We think this may be related 
to the sequestration effect associated with phagocytic cells. 
It is well established that phagocytes, which are abundant 
in the reticuloendothelial system, in liver, kidney, spleen 
and lung tissues, can trigger the process of phagocytic 
recognition and subsequent blood clearance. Brucine can 
be quantified in rat brain tissue, and we postulate that LB 
passes through the blood–brain barrier and plays a role 
in the central nervous system after dermal administration. 
LB does not appear to cause toxicity in the brain or the 
kidneys.
After dermal administration, LB can rapidly enter   tissues. 
The concentrations in some organs were higher than that in 
blood. However, the concentration was lower than for normal 
brucine. It can be hypothesized that LB would cause less tox-
icity to organs than normal brucine. LB could be effective for 
pain relief and as an anti-inflammatory agent while avoiding 
the side effects associated with normal brucine. This estab-
lished LB as having targeted, sustained release, with locally 
potent therapeutic effects, and low systemic   toxicity. This 
study suggests that clinical use of LB is feasible, thus avoid-
ing problems associated with traditional forms of   brucine. 
This provides a basis for new analgesic preparations using 
Strychnos nux-vomica L.
Conclusion
A previous study13 showed the analgesic and   anti-inflammatory 
properties of LB after dermal administration and estab-
lished there were no apparent side effects locally or 
systemically.
This study of skin pharmacokinetics showed that after 
dermal administration, the concentration of LB in rats’ skin 
changed over time. LB encapsulated in liposomes could form 
a sustained release system in skin. The plasma pharmacoki-
netics study showed that 36 hours after dermal administra-
tion, brucine could not be detected in plasma, indicating that 
LB was accumulated mainly in local skin and minimally in 
blood circulation.
Table 3 Plasma PK parameters, iv of brucine (n = 5)
Compartment parameter Unit Mean SD
t1/2 hours 0.88 0.04
Ke 1/hours 0.79 0.04
V1 L/kg 4.92 0.28
cL L/hours/kg 3.88 0.13
AUc(0-t) mg/L × hours 1.15 0.05
AUc(0-∞) mg/L × hours 1.29 0.04
Abbreviations: AUc, area under the curve; cL, clearance; iv, intravenous injection; 
Ke, elimination rate constant; PK, Pharmacokinetics; V1, central volume.
Table 4 Plasma PK parameters, iv of LB (n = 5)
Compartment parameter Unit Mean SD
t1/2α hours 0.12 0.04
t1/2β hours 2.37 0.48
V1 L/kg 4.54 0.05
cL L/hours/kg 2.62 0.19
AUc(0-t) mg/L × hours 1.39 0.06
AUc(0-∞) mg/L × hours 1.92 0.15
K10 1/hours 0.58 0.04
K12 1/hours 2.93 2.82
K21 1/hours 3.23 1.16
Abbreviations: AUc, area under the curve; cL, clearance; iv, intravenous injection; 
K10–12, microconstants; LB, liposomal brucine; PK, Pharmacokinetics; V1, central 
volume.
organs and tissues but the concentrations differed with the 
organs and tissues involved. The concentrations in organs and 
  tissues showed concentration-time effects for the dermally 
administered product.
Figure 9 shows brucine concentration over time in rat 
  tissues after dermal administration of LB. After dermal 
administration, LB distributed widely and could be detected 
in the liver, heart, spleen, lung, kidney, brain and muscle 
tissue.
As shown in Figure 9, with the exception of heart and 
brain, the concentration rose to 50% of the maximum 
concentration in all tissues after 0.5 hours and peaked at 
1.5 hours. It decreased to half of the maximum concentra-
tion after 2 hours. The concentration increased slightly at 
4 hours, then declined gradually. It could not be measured 
after 12 hours. These data showed LB was absorbed quickly 
but did not accumulate in vivo. The peak values of bru-
cine in lung and muscle occurred after 1.5 hours and later 
concentrations were lower than those in liver, kidney and 
spleen. The concentration was higher in kidney than in liver 
and lung and the rate of absorption was faster. These results 
suggested brucine was absorbed well but excreted quickly. 
The concentration trend in muscle showed characteristics of International Journal of Nanomedicine
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